GEN Exclusives

More »

GEN News Highlights

More »
Feb 22, 2011

Novartis to Assess Quanterix’ Single Molecule Array Platform for Diagnostic Use

  • Novartis inked a deal to evaluate Quanterix’ Single Molecule Array (SiMoA™) technology for the detection of an undisclosed neuron-specific protein target. SiMoA is designed to validate novel, low-abundance biomolecules from a single droplet of blood and other tissues using digital technology. Quanterix says that it offers 1,000 times the sensitivity of analog-only array technologies.

    SiMoA isolates individual immunocomplexes on beads using standard ELISA reagents. The beads are loaded into arrays containing femtoliter-sized wells, and the arrays are sealed in the presence of the enzyme substrate and fluorescently imaged. By using high-density arrays containing 50,000 to 500,000 wells, hundreds to thousands of single immunocomplexes can be detected simultaneously.

    “Through this collaborative project, we hope to leverage the 1000-fold sensitivity improvement of SiMoA technology to develop a novel class of valuable diagnostic tests that will provide greater insight into disease and improve patient outcomes,” states David Okrongly, Ph.D., Quanterix President and CEO.

    Founded in 2007, privately held Quanterix a year later realized $15 million in a Series A financing. Last November it won a $733,437 grant under the Qualifying Therapeutic Discovery Project for the development of SiMoA. The technology has the potential to be applied to disease diagnosis, therapy selection, and disease monitoring.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »